# An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

> **NCT02038673** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 86 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** ASP5878

## Key facts

- **NCT ID:** NCT02038673
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-05
- **Primary completion:** 2017-07-19
- **Final completion:** 2017-07-19
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038673, "An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02038673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*